Research programme: T-cell modulators - Medigene AG

Drug Profile

Research programme: T-cell modulators - Medigene AG

Alternative Names: Adoptive T-cell therapy; T-cell antibodies - TABs; TCR modified T-cells; TCR-specific antibodies-Medigene Immunotherapies

Latest Information Update: 21 Nov 2016

Price : $50

At a glance

  • Originator Trianta Immunotherapies
  • Developer MediGene AG
  • Class Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; T-cell leukaemia

Most Recent Events

  • 25 Jul 2016 MediGene AG has patent protection for T-cell modulators in USA, Europe, Australia, and Canada
  • 07 Nov 2014 Trianta Immunotherapies is now called Medigene Immunotherapies
  • 27 Jan 2014 Medigene AG acquires Trianta Immunotherapies GmBH
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top